User menu

Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus.

Bibliographic reference Pavel, Marianne ; Unger, Nicole ; Borbath, Ivan ; Ricci, Sergio ; Hwang, Tsann-Long ; et. al. Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus.. In: Targeted Oncology : biotherapies for the clinicians in oncology, Vol. 11, no.5, p. 667-675 (2016)
Permanent URL http://hdl.handle.net/2078.1/180143
  1. Vinik Aaron I., Woltering Eugene A., Warner Richard R. P., Caplin Martyn, O'Dorisio Thomas M., Wiseman Gregory A., Coppola Domenico, Go Vay Liang W., NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor : , 10.1097/mpa.0b013e3181ebaffd
  2. Yao James C., Hassan Manal, Phan Alexandria, Dagohoy Cecile, Leary Colleen, Mares Jeannette E., Abdalla Eddie K., Fleming Jason B., Vauthey Jean-Nicolas, Rashid Asif, Evans Douglas B., One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, 10.1200/jco.2007.15.4377
  3. Kulke Matthew H., Benson Al B., Bergsland Emily, Berlin Jordan D., Blaszkowsky Lawrence S., Choti Michael A., Clark Orlo H., Doherty Gerard M., Eason James, Emerson Lyska, Engstrom Paul F., Goldner Whitney S., Heslin Martin J., Kandeel Fouad, Kunz Pamela L., Kuvshinoff Boris W., Moley Jeffrey F., Pillarisetty Venu G., Saltz Leonard, Schteingart David E., Shah Manisha H., Shibata Stephen, Strosberg Jonathan R., Vauthey Jean-Nicolas, White Rebekah, Yao James C., Freedman-Cass Deborah A., Dwyer Mary A., Neuroendocrine Tumors, 10.6004/jnccn.2012.0075
  4. Frilling Andrea, Modlin Irvin M, Kidd Mark, Russell Christopher, Breitenstein Stefan, Salem Riad, Kwekkeboom Dik, Lau Wan-yee, Klersy Catherine, Vilgrain Valerie, Davidson Brian, Siegler Mark, Caplin Martyn, Solcia Enrico, Schilsky Richard, Recommendations for management of patients with neuroendocrine liver metastases, 10.1016/s1470-2045(13)70362-0
  5. Falconi Massimo, Bartsch Detlef Klaus, Eriksson Barbro, Klöppel Günter, Lopes José M., O'Connor Juan M., Salazar Ramón, Taal Babs G., Vullierme Marie Pierre, O'Toole Dermot, ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors, 10.1159/000335587
  6. Pape Ulrich-Frank, Perren Aurel, Niederle Bruno, Gross David, Gress Thomas, Costa Frederico, Arnold Rudolf, Denecke Timm, Plöckinger Ursula, Salazar Ramon, Grossman Ashley, ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas, 10.1159/000335629
  7. Pavel Marianne, Baudin Eric, Couvelard Anne, Krenning Eric, Öberg Kjell, Steinmüller Thomas, Anlauf Martin, Wiedenmann Bertram, Salazar Ramon, ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary, 10.1159/000335597
  8. National Comprehensive Cancer Network. Clinical practice guideline in oncology. Neuroendocrine tumors version 1.2015. http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf (Accessed on March 2, 2015)
  9. Pavel Marianne E, Hainsworth John D, Baudin Eric, Peeters Marc, Hörsch Dieter, Winkler Robert E, Klimovsky Judith, Lebwohl David, Jehl Valentine, Wolin Edward M, Öberg Kjell, Van Cutsem Eric, Yao James C, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study, 10.1016/s0140-6736(11)61742-x
  10. Yao James C., Shah Manisha H., Ito Tetsuhide, Bohas Catherine Lombard, Wolin Edward M., Van Cutsem Eric, Hobday Timothy J., Okusaka Takuji, Capdevila Jaume, de Vries Elisabeth G.E., Tomassetti Paola, Pavel Marianne E., Hoosen Sakina, Haas Tomas, Lincy Jeremie, Lebwohl David, Öberg Kjell, Everolimus for Advanced Pancreatic Neuroendocrine Tumors, 10.1056/nejmoa1009290
  11. Swinburn P., Wang J., Chandiwana D., Mansoor W., Lloyd A., Elicitation of health state utilities in neuroendocrine tumours, 10.3111/13696998.2012.670175
  12. Davies A.H.G., Larsson G., Ardill J., Friend E., Jones L., Falconi M., Bettini R., Koller M., Sezer O., Fleissner C., Taal B., Blazeby J.M., Ramage J.K., Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours, 10.1016/j.ejca.2005.10.025
  13. EuroQol - a new facility for the measurement of health-related quality of life, 10.1016/0168-8510(90)90421-9
  14. Rabin Rosalind, Charro Frank de, EQ-SD: a measure of health status from the EuroQol Group, 10.3109/07853890109002087
  15. Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., Haes J. C. J. M. d., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P. B., Schraub S., Sneeuw K., Sullivan M., Takeda F., The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, 10.1093/jnci/85.5.365
  16. Yadegarfar G, Friend L, Jones L, Plum L M, Ardill J, Taal B, Larsson G, Jeziorski K, Kwekkeboom D, Ramage J K, Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours, 10.1038/bjc.2012.560
  17. National Cancer Institute. Common Terminology Criteria for Adverse Events [CTCAE], version 4.0. May 29, 2009. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (Accessed on September 1, 2014)